# A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

> **NCT01342965** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 217 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT01342965
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-07
- **Final completion:** 2014-04
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2015-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01342965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01342965, "A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01342965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*